Cost-sharing and initiation of disease-modifying therapy for multiple sclerosis

American Journal of Managed Care

Volumn 18, Issue 8, 2012, Pages 460-464

  Romley, John ^a   Goldman, Dana ^a   Eber, Michael ^b   Dastani, Homa ^c   Kim, Edward ^c   Raparla, Swetha ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b PRECISION HEALTH ECONOMICS   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMORBIDITY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE MODIFYING THERAPY; FOLLOW UP; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PATIENT ASSESSMENT; PRIORITY JOURNAL; TREATMENT PLANNING;

ADULT; COST SHARING; FEMALE; HEALTH BENEFIT PLANS, EMPLOYEE; HUMANS; IMMUNOMODULATION; INSURANCE CLAIM REVIEW; LONGITUDINAL STUDIES; MALE; MULTIPLE SCLEROSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84869224662     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Squires DA. The U.S. health system in perspective: a comparison of twelve industrialized nations. Issue Brief (Commonwealth Fund). 2011;16:1-14.
2. Joyce GF, Escarce JJ, Solomon MD, Goldman DP. Employer drug benefit plans and spending on prescription drugs. JAMA. 2002;288(14):1733-1739.
3. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61-69.
4. Chandra A, Gruber J, McKnight R. Patient cost-sharing and hospitalization offsets in the elderly. Am Econ Rev. 2010;100(1):193-213.
5. Newhouse JP. Consumer-directed health plans and the RAND Health Insurance Experiment. Health Aff (Millwood). 2004;23(6):107-113.
6. Lichtenberg FR. Do (more and better) drugs keep people out of hospitals? Am Econ Rev. 1996;86(2):384-388.
7. Philipson TJ, Mozaffari E, Maclean JR. Pharmacy cost sharing, antiplatelet therapy utilization, and health outcomes for patients with acute coronary syndrome. Am J Manag Care. 2010;16(4):290-297.
8. Goldman DP, Joyce GF, Karaca-Mandic P. Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. Am J Manag Care. 2006;12(1):21-28.
9. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648): 1502-1517.
10. Johnson KP. Control of multiple sclerosis relapses with immunomodulating agents. J Neurol Sci. 2007;256(suppl 1):S23-S28.
11. Society NMS. Multiple sclerosis: just the facts. 2010.
12. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. 1995. Neurology. 2001;57(12)(suppl 5):S16-S24.
13. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial: The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1995;45(7):1277-1285.
14. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39(3):285-294.
15. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis: PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352(9139):1498-1504.
16. Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006;66(11):1696-1702.
17. Gleason PP, Starner CI, Gunderson BW, Schafer JA, Sarran HS. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications. J Manag Care Pharm. 2009;15(8): 648-658.
18. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291(19):2344-2350.
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
20. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-1139.
21. Goldman DP, Jena AB, Lakdawalla DN, Malin JL, Malkin JD, Sun E. The value of specialty oncology drugs. Health Serv Res. 2010;45(1): 115-132.
22. Duddy M, Haghikia A, Cocco E, et al. Managing MS in a changing treatment landscape. J Neurol. 2011;258(5):728-739.
23. Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and longterm disability. Brain. 2010;133(pt 7):1914-1929.
24. Sormani MP, Bonzano L, Roccatagliata L, Mancardi GL, Uccelli A, Bruzzi P. Surrogate endpoints for EDSS worsening in multiple sclerosis: a meta-analytic approach. Neurology. 2010;75(4):302-309.
25. Curkendall SM, Wang C, Johnson BH, et al. Potential health care cost savings associated with early treatment of multiple sclerosis using disease-modifying therapy. Clin Ther. 2011;33(7):914-925.
26. Duke KS, Raube K, Lipton HL. Patient-assistance programs: assessment of and use by safety-net clinics. Am J Health Syst Pharm. 2005; 62(7):726-731.
27. NeedyMeds. http://www.needymeds.org/drug-list.taf. Published 2011. Accessed January 9, 2012.
28. Joyce GF, Goldman DP, Karaca-Mandic P, Lawless GD. Impact of specialty drugs on the use of other medical services. Am J Manag Care. 2008;14(12):821-828.